Efficacy and Safety Study of Oral Solithromycin (CEM-101) Compared to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia

Exclusion Criteria

• •Ventilator-associated pneumonia
• •Known anatomical or pathological bronchial obstruction or a history of bronchiectasis or documented severe chronic obstructive pulmonary disease
• •Hospitalization within 90 days or residence in a long-term care facility within 30 days prior to the onset of symptoms
• •Presence of known:
• •1. Viral or fungal pneumonia
• •2. Pneumocystis jiroveci pneumonia
• •3. Aspiration pneumonia
• •4. Other non-infectious causes of pulmonary infiltrates (e.g. pulmonary embolism, hypersensitivity pneumonia, congestive heart failure)
• •5. Primary or metastatic lung cancer
• •6. Cystic fibrosis
• •7. Active or suspected tuberculosis
• •Known HIV or myasthesia gravis